As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a study titled: Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
Independent expert commentary is provided by Professor Paul Bird, a Rheumatologist in private practice and Conjoint Professor at the University of New South Wales.
Please login below to download this issue (PDF)